Innate Pharma (OTCMKTS:IPHYF) and Inotiv (NASDAQ:NOTV) Head to Head Comparison

Innate Pharma (OTCMKTS:IPHYF) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Innate Pharma and Inotiv’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Inotiv	-17.14%	-56.77%	-8.91%

Valuation & Earnings

This table compares Innate Pharma and Inotiv”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19 million	13.57	-$55.64 million	N/A	N/A
Inotiv	$507.36 million	0.00	-$68.62 million	($2.53)	-0.01

Innate Pharma has higher earnings, but lower revenue than Inotiv.

Volatility & Risk

Innate Pharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Inotiv has a beta of 3.77, suggesting that its stock price is 277% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Innate Pharma and Inotiv, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0	0	0	0	0.00
Inotiv	1	0	1	0	2.00

Inotiv has a consensus price target of $1.50, suggesting a potential upside of 7,400.00%. Given Inotiv’s stronger consensus rating and higher possible upside, analysts plainly believe Inotiv is more favorable than Innate Pharma.

Insider and Institutional Ownership

18.2% of Inotiv shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 7.8% of Inotiv shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.